Harjeet Singh

List of Publications by Year
in descending order

21 papers	1,670 citations	687363 13 h-index	794594 19 g-index
21 all docs	21 docs citations	21 times ranked	2525 citing authors

#	Article	IF	Citations
1	Designed improvement to T-cell immunotherapy by multidimensional single cell profiling. , 2021, 9, e001877.		12
2	Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia. Leukemia, 2021, 35, 3282-3286.	7.2	61
3	Chimeric Antigen Receptor Therapy: How Are We Driving in Solid Tumors?. Biology of Blood and Marrow Transplantation, 2020, 26, 1759-1769.	2.0	9
4	TIMING 2.0: high-throughput single-cell profiling of dynamic cellâ€“cell interactions by time-lapse imaging microscopy in nanowell grids. Bioinformatics, 2019, 35, 706-708.	4.1	12
5	Defining potency of CAR⁺ T cells: Fast and furious or slow and steady. OncoImmunology, 2019, 8, e1051298.	4.6	4
6	Rapid Personalized Manufacture (RPM) of Sleeping Beauty System-Generated NY-ESO-1-Specific TCR-T Cells Co-Expressing Membrane-Bound IL-15 Yields Anti-Tumor Responses. Blood, 2019, 134, 3218-3218.	1.4	0
7	Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models. Oncogene, 2018, 37, 3686-3697.	5.9	45
8	Gene Therapy with the Sleeping Beauty Transposon System. Trends in Genetics, 2017, 33, 852-870.	6.7	92
9	Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors. PLoS ONE, 2016, 11, e0159477.	2.5	50
10	Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E7788-E7797.	7.1	320
11	Very Rapid Production of CAR+ T-Cells upon Non-Viral Gene Transfer Using the Sleeping Beauty System. Blood, 2016, 128, 2807-2807.	1.4	2
12	Combination Immunotherapy with NY-ESO-1-Specific CAR+ T Cells with T-Cell Vaccine Improves Anti-Myeloma Effect. Blood, 2016, 128, 3366-3366.	1.4	14
13	Individual Motile CD4+ T Cells Can Participate in Efficient Multikilling through Conjugation to Multiple Tumor Cells. Cancer Immunology Research, 2015, 3, 473-482.	3.4	85
14	Genetic Engineering of T Cells to Target HERV-K, an Ancient Retrovirus on Melanoma. Clinical Cancer Research, 2015, 21, 3241-3251.	7.0	83
15	Automated profiling of individual cellâ€“cell interactions from high-throughput time-lapse imaging microscopy in nanowell grids (TIMING). Bioinformatics, 2015, 31, 3189-3197.	4.1	45
16	Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity. Cancer Research, 2015, 75, 3505-3518.	0.9	327
17	Pre-Emptive Donor Lymphocyte Infusion with CD19-Directed, CAR-Modified T Cells Infused after Allogeneic Hematopoietic Cell Transplantation for Patients with Advanced CD19+ Malignancies. Blood, 2015, 126, 862-862.	1.4	11
18	A new approach to gene therapy using Sleeping Beauty to genetically modify clinicalâ€grade T cells to target <scp>CD</scp>19. Immunological Reviews, 2014, 257, 181-190.	6.0	121

#	Article	IF	Citations
19	Manufacture of Clinical-Grade CD19-Specific T Cells Stably Expressing Chimeric Antigen Receptor Using Sleeping Beauty System and Artificial Antigen Presenting Cells. PLoS ONE, 2013, 8, e64138.	2.5	143
20	Redirecting Specificity of T-Cell Populations For CD19 Using the Sleeping Beauty System. Cancer Research, 2008, 68, 2961-2971.	0.9	232
21	Efficacy of â€˜Off-the-Shelfâ€™, Commercially-Available, Third-Party Mesenchymal Stem Cells (MSC) in Ex Vivo Cord Blood (CB) Co-Culture Expansion.. Blood, 2007, 110, 4106-4106.	1.4	2